Sabra Healthcare REIT (NASDAQ:SBRA) Releases FY 2026 Earnings Guidance

Sabra Healthcare REIT (NASDAQ:SBRA) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.540-1.550 for the period, compared to the consensus earnings per share estimate of 1.520.

Sabra Healthcare REIT Stock Up 2.0%

Sabra Healthcare REIT stock traded up $0.40 on Tuesday, hitting $20.12. 452,205 shares of the stock traded hands, compared to its average volume of 2,652,586. Sabra Healthcare REIT has a 1 year low of $17.53 and a 1 year high of $22.77. The firm has a market cap of $5.14 billion, a P/E ratio of 77.36, a price-to-earnings-growth ratio of 1.73 and a beta of 0.63. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.95. The business’s fifty day simple moving average is $19.86 and its 200 day simple moving average is $19.96.

Sabra Healthcare REIT (NASDAQ:SBRA) last released its earnings results on Monday, November 2nd. The real estate investment trust reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.05). The business had revenue of $249.57 million during the quarter, compared to analysts’ expectations of $236.64 million. Sabra Healthcare REIT had a return on equity of 2.34% and a net margin of 7.61%. The firm’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.38 earnings per share. As a group, sell-side analysts forecast that Sabra Healthcare REIT will post 1.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SBRA has been the topic of a number of recent research reports. Huntington began coverage on shares of Sabra Healthcare REIT in a report on Thursday, September 10th. They issued an “outperform” rating and a $23.00 price objective on the stock. Wells Fargo & Company decreased their target price on shares of Sabra Healthcare REIT from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Monday, October 19th. Raymond James Financial upgraded shares of Sabra Healthcare REIT from an “underperform” rating to a “market perform” rating in a report on Thursday, August 6th. Barclays dropped their price target on Sabra Healthcare REIT from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 13th. Finally, Mizuho set a $21.00 price target on Sabra Healthcare REIT in a research report on Monday, August 31st. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.50.

Insider Transactions at Sabra Healthcare REIT

In other news, CEO Richard Matros sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $20.83, for a total value of $4,166,000.00. Following the transaction, the chief executive officer owned 1,657,686 shares in the company, valued at approximately $34,529,599.38. This represents a 10.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.09% of the company’s stock.

Sabra Healthcare REIT News Summary

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Sabra raised its full-year 2026 EPS guidance to $1.540–$1.550, above the prior consensus estimate of $1.520, signaling improved expectations for the business. Sabra Reports Third Quarter 2026 Results; Updates 2026 Guidance
• Positive Sentiment: Third-quarter revenue reached approximately $249.6 million, beating the $236.6 million analyst estimate and increasing 31.4% from the prior-year period. Sabra Q3 Revenue Earnings Flash
• Positive Sentiment: Funds from operations, a key REIT performance measure, were reported at $0.40–$0.41 per share, ahead of the roughly $0.40 consensus estimate and up from $0.38 a year earlier. Normalized AFFO was $0.41 per share, while AFFO was $0.45. Sabra Healthcare Tops Q3 FFO and Revenue Estimates
• Positive Sentiment: The company also declared its quarterly dividend, supporting the income appeal of the healthcare REIT. Sabra Reports Third-Quarter Results and Declares Quarterly Dividend
• Negative Sentiment: Reported net income was $0.11 per diluted share, below the $0.16 analyst consensus and down from $0.38 a year ago. The GAAP earnings shortfall and relatively low 7.61% net margin remain risks, although investors appear to be placing greater weight on FFO and the raised outlook. Sabra Third-Quarter Earnings Results

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.